Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept in resistant advanced ovarian cancer
NCT00327171Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2006
- Primary completion
- Apr 2008
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 11
01
Overview
A Phase 2 trial of aflibercept in Ovarian Epithelial Adenocarcinoma, sponsored by Sanofi. Started May 2006; status: completed.
02
Drugs
aflibercept
03
Conditions
Ovarian Epithelial Adenocarcinoma
Beyond the preview
Go deeper on NCT00327171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00327171.